BlackRock Investment Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

BlackRock Investment Management’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$14K	Sell	3,197 -1	-0%	-$6	﹤0.01%	3498
2016 Q3	$31K	Buy	3,198 +962	+43%	+$6.82K	﹤0.01%	3324
2016 Q2	$13K	Sell	2,236 -53,528	-96%	-$363K	﹤0.01%	3542
2016 Q1	$425K	Buy	55,764 +1,023	+2%	+$7.88K	﹤0.01%	2957
2015 Q4	$729K	Buy	54,741 +451	+0.8%	+$7.77K	﹤0.01%	2806
2015 Q3	$893K	Sell	54,290 -5,683	-9%	-$117K	﹤0.01%	2674
2015 Q2	$1.35M	Buy	59,973 +14,259	+31%	+$226K	﹤0.01%	2552
2015 Q1	$447K	Buy	45,714 +7,956	+21%	+$78K	﹤0.01%	3010
2014 Q4	$430K	Buy	37,758 +573	+2%	+$6.22K	﹤0.01%	3073
2014 Q3	$428K	Buy	37,185 +3,987	+12%	+$60.9K	﹤0.01%	3051
2014 Q2	$645K	Buy	+33,198	New	+$586K	﹤0.01%	2898

Other funds holding CASC

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BlackRock Investment Management's CASC Position: Q4 2016 in Review

BlackRock Investment Management reduced its Cascadian Therapeutics, Inc. (CASC) stake by 0.03% in Q4 2016, selling an estimated $6 and leaving 3,197 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #3498.

BlackRock Investment Management first reported a position in CASC in Q2 2014 and has held it in 11 quarters since. The position peaked at $1.35M in Q2 2015. 57 funds tracked by Wall St. Rank hold CASC as of Q4 2016.

BlackRock Investment Management held 3,197 shares of Cascadian Therapeutics, Inc. worth $14K as of Q4 2016.
BlackRock Investment Management sold 1 Cascadian Therapeutics, Inc. share in Q4 2016, an estimated $6.
Cascadian Therapeutics, Inc. made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3498 holding.
BlackRock Investment Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2014 and has held it in 11 quarters since.
BlackRock Investment Management's Cascadian Therapeutics, Inc. position peaked at $1.35M in Q2 2015.
57 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.